The EGFR inhibitor erlotinib has been used as a monotherapy for patients with non-small cell lung cancer (NSCLC) and combined with gemcitabine for patients with pancreatic cancer to prolong their survival [37, 38]. Here, EGFR is linked to non-small cell lung carcinoma.